Navigation Links
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
Date:5/18/2009

Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety

Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time

SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced additional positive safety and efficacy results from its Phase IIb clinical trial known as the Petal Study (603 study) using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The Petal Study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment followed by six months of no treatment. Database lock and unblinding of the full 48 week data set has provided more insight on the clinical benefits and safety profile of elagolix for the treatment of pain associated with endometriosis.

"As expected, elagolix did not induce significant bone loss over the six-month follow up phase of the Petal Study," said Chris O'Brien, MD, Neurocrine's Chief Medical Officer. "Additionally, we are seeing for the first time an oral GnRH antagonist with a rapid and sustained symptom reduction during treatment that also provides a statistically and clinically significant improvement in symptoms which persists after discontinuation of therapy. These are intriguing results and raise the possibility that elagolix treatment may have a disease modifying effect."

Key findings include the following:

Bone Safety: As previously reported, the primary endpoint of the Petal Study, impact on bone mineral density (BMD), was
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
4. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
7. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
10. International Student Insurance Announces Website Redesign
11. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... ... Good health and a good cause paired up at The Barclays this ... $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. After ... Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to add more ...
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... WI (PRWEB) , ... September 02, 2015 , ... ... Cypress Benefit Administrators is taking action after seeing a significant increase ... TPA’s Argus Claim Review division has found many cases of OON ASCs encouraging ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... Wash. , Feb. 4 The Carol Milgard Breast ... and Drug Administration (FDA) for adhering to the most rigorous quality ... (MQSA).  Receiving the "All Items in Compliance" rating from the FDA ... not received this high quality standard.   , John Peixotto ...
... PALM BEACH, Fla. , Feb. 4 The American ... suffer from some type of cardiovascular disease. Many of those people ... event like the Super Bowl or World Cup where the tension ... rates from heart attacks in 2002 and 2001, doctors in ...
... cancer is the second leading cause of cancer-related deaths in ... of screening for this disease, rates of screening for colorectal ... cancer, particularly breast and cervical. Although the screening rates in ... from 20-30 percent in 1997 to nearly 55 percent in ...
... for athletes to cheat, researchers say , THURSDAY, Feb. 4 ... scientists are warning of a new breed of performance-enhancing agents ... to detect. , , Some researchers are already ... how they can modify genes to boost endurance or muscle ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , , ... /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), ... materials for,use in pharmaceutical, nutraceutical and food production, today announced,preliminary ... Huifeng Bio-Pharmaceutical Technology anticipates revenues between $13,million ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Panel calls for reducing colorectal cancer deaths by striking down barriers to screening 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 3
(Date:9/2/2015)... DIEGO , Sept. 2, 2015  MEI Pharma, ... on the clinical development of novel therapies for cancer, ... 30, 2015. Logo - http://photos.prnewswire.com/prnh/20140805/133834 ... fiscal year, I am quite pleased with how the ... Daniel P. Gold , Ph.D., President and Chief Executive ...
(Date:9/2/2015)... 2015  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... has entered into a definitive agreement under which Valeant ... (NASDAQ: SURG ) for $6.50 per share in ... stockholders will receive additional cash payments of up to ... following the closing.  The transaction is expected to close ...
(Date:9/2/2015)... , Sept. 2, 2015 Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced today ... at both the FBR Second Annual Healthcare Conference and ... follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor meetings ...
Breaking Medicine Technology:MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2
... Md., Dec. 1, 2011 The Food and Drug Administration ... products, including a potentially contaminated nasal spray ... unapproved drug sold as a testosterone booster ... alerts were prompted by reports FDA received from health care ...
... WASHINGTON, Dec. 1, 2011  Assembly Bill 5502-B—transmitted to ... of many prescriptions in New York by 10 ... If enacted, the Bill would prohibit consumers from ... The Federal Trade Commission warns that ...
Cached Medicine Technology:NY Pharmacy Bill Sent to Governor Would Raise Drug Prices 2NY Pharmacy Bill Sent to Governor Would Raise Drug Prices 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: